Previous 10 | Next 10 |
2024-01-11 09:59:58 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list For further detail...
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to initiate first-in-human studies of ATH-1105 to treat amyotrophic lateral sclerosis i...
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach focused on HGF modulation for treatme...
VACAVILLE, CA / ACCESSWIRE / January 2, 2024 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNR) ("Athena" or the "Company") is pleased to announce that it has closed its previously announced acquisition (the "Acquisition") of 10,000,000 common shares in the capital of Nubian Resources Ltd., a comp...
2024-01-02 10:27:51 ET More on Athira Pharma Seeking Alpha’s Quant Rating on Athira Pharma Historical earnings data for Athira Pharma Financial information for Athira Pharma For further details see: Athira Pharma 10% owner Perceptive Advisors discl...
2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/...
Objective is to Refine 2024 Drill Targets RENO, NV / ACCESSWIRE / December 12, 2023 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") is pleased to announce it has contracted with Zonge International, Inc. to perform an IP/Resistivity (the " Survey ") at its 10...
NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December 6-7, 2023. The presentation schedule is su...
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Si...
News, Short Squeeze, Breakout and More Instantly...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western Distri...